Cirrhotic Cardiomyopathy Based on Point-of-care Echocardiography, Biomarkers and Histology

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorPost Graduate Institute of Medical Education and Research, Chandigarh

About this trial

Cirrhotic cardiomyopathy is associated with increased risk of complications like hepatorenal syndrome, refractory ascites, impaired response to stressors including sepsis, bleeding or transplantation, poor health related quality of life and increased morbidity and mortality. Left ventricular diastolic dysfunction (LVDD) is associated with risk of hepatorenal syndrome (HRS) , septic shock. , heart failure in the perioperative period following liver transplantation, and after trans-jugular intrahepatic portosystemic shunt (TIPS) insertion . The echocardiographic E/e' ratio is a predictor of survival in LVDD, with multiple studies, including prospective data from our Centre.

Eligibility criteria

Qualifiers

Age range of 18-65 years

Cirrhosis with critical illness admitted to the Liver Intensive Care Unit

Disqualifiers

Age >65 years

Chronic renal disease

Pregnancy and peripartum cardiomyopathy

Valvular heart disease

Trial design

Treatments tested in this trial

  • Echocardiographic assessment
  • Histopathology and Immunohistochemistry

Treatment groups

150 Participants
are divided into 1 treatment group

Locations

1

Map coordinates are unavailable for these locations. Locations are shown below instead.

Dr. Madhumita PremkumarRecruiting160012, Sector-12, ChandigarhIndiaIndia